TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A physician’s commentary argues that persistent reports of cognitive change deserve careful evaluation even when comprehensive testing does not show impairment. Subjective cognitive decline is not a diagnosis of Alzheimer’s, and the article says symptoms can have many causes; repeated testing and, for selected patients, biomarkers may help guide assessment.
People who report persistent changes in memory or thinking may merit follow-up even when cognitive test scores remain within the expected range, geriatrician and memory-care physician Dr. Nathaniel Chin argues in a commentary published October 27 by Being Patient. Chin describes subjective cognitive decline (SCD) as a reason to establish a careful baseline and look for possible causes—not as proof of Alzheimer’s disease.
SCD refers to a person’s ongoing sense that their thinking has worsened compared with their previous abilities, despite testing that does not show objective cognitive impairment. Chin stresses that a brief screening test and a comprehensive cognitive evaluation are not interchangeable: screening typically takes five to 15 minutes, while a full evaluation may take an hour or longer and examine several areas of cognition.
Even a comprehensive assessment generally compares someone with people of a similar age, rather than with that person’s own earlier performance. Chin says an individual whose abilities were previously well above average could experience a meaningful decline and still score in the average range. A well-established baseline and repeat testing over time can help clinicians look for consistent changes that a single result may not reveal.
Chin says evaluation should also consider factors that can affect perceived thinking, including sleep problems, medications, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging. He describes a fuller clinical approach as establishing a baseline, investigating other contributors, seeking observations from someone who knows the patient when possible, and monitoring changes rather than simply waiting for a low score.
Why Earlier Follow-Up Can Help
The commentary’s central point is about when to investigate, not whether a person’s concern confirms Alzheimer’s. Chin argues that waiting until test results cross an impairment threshold could miss a period when clinicians can document change, address other health factors and discuss risk reduction or further assessment with the patient.
That distinction matters for patients and families because a normal result can be reassuring without resolving why someone feels different. A structured assessment can create a reference point for future visits and help separate a persistent pattern from symptoms that fluctuate with stress, sleep or other conditions. Chin presents this as a clinical rationale for taking concerns seriously while avoiding a premature Alzheimer’s label.
The article also discusses biomarkers as a possible part of assessment for selected patients. Blood tests, cerebrospinal fluid testing and amyloid PET can be used to investigate biological changes associated with Alzheimer’s, Chin writes. The source material does not establish that these tests are appropriate for everyone with SCD or that they can, by themselves, predict an individual’s future course.
Products Worth Considering
Cuisinart 14-Cup Food Processor, 720-Watt Motor, Stainless Steel, DFP-14BCNY
Cuisinart Dual Basket Air Fryer, 11 Qt, ADZ-112
Le Creuset Enameled Cast Iron Round Bread Oven, 9.5-Inch, Cerise
As an affiliate, we earn on qualifying purchases.
How Clinicians Define SCD
The commentary was written by Dr. Nathaniel Chin, a geriatrician and memory-care physician at UW Health and an associate professor in the University of Wisconsin–Madison’s Department of Medicine. He also serves as medical director and Clinical Core co-leader of the Wisconsin Alzheimer’s Disease Research Center. The article is a physician’s perspective on assessment and care, not a report of a new clinical trial or a newly announced guideline.
Chin describes a framework called “SCD plus,” developed by Dr. Frank Jessen of the University of Cologne and colleagues in the international Subjective Cognitive Decline Initiative. Features that may make SCD more concerning include memory-focused changes, onset within the past five years or at age 60 or older, worry about the change, persistence, seeking medical help, and confirmation by someone who knows the person well. These features do not establish Alzheimer’s; Chin says that several occurring together can justify closer attention.
He contrasts a longstanding, intermittent concern linked to poor sleep or stress with a more recent and persistent memory change that is also noticed by a spouse and prompts an evaluation. Both people could score within the normal range, but the pattern and circumstances would lead Chin to consider their cases differently. The example illustrates why a score alone may not capture the full clinical picture.
What a Normal Score Cannot Settle
SCD does not identify its cause. The same reported change may reflect Alzheimer’s-related biology, another medical or psychological factor, or normal variation. The “SCD plus” features described by Chin can raise concern, but none proves that Alzheimer’s disease is present.
The article does not provide new study results, estimates of how often SCD leads to Alzheimer’s, or a test-based prediction for any individual. It also does not specify which patients should receive blood biomarker testing, spinal fluid testing or amyloid PET, or how those results should change care. Those decisions and the meaning of results remain matters for clinical evaluation.
It is also not clear from the commentary how often people with SCD should repeat cognitive testing or which particular assessment is best in every case. Chin’s recommendations are a physician’s perspective, and a normal screening score alone is not the same as the comprehensive evaluation he says is needed to characterize SCD.
Monitoring and Further Assessment
For people with ongoing concerns, Chin’s proposed next steps are to seek an appropriate clinical evaluation, document a thorough cognitive baseline, consider possible contributors and, when feasible, include observations from a trusted person. Repeat testing over time may show whether abilities remain stable or change consistently.
For selected patients, clinicians may also consider Alzheimer’s biomarkers as part of determining whether biological changes are present. The commentary does not announce a new testing program or set a timetable for expanded access. The practical next step it describes is individualized assessment and follow-up, with the cause of reported changes still to be determined.
Key Questions
What is subjective cognitive decline?
Subjective cognitive decline is a persistent sense that memory or thinking has worsened compared with a person’s previous abilities, even though testing does not show objective impairment.
Does SCD mean someone has Alzheimer’s disease?
No. Chin describes SCD as an experience, not an explanation. Sleep, medications, mood, medical conditions, hearing loss, stress and other factors can affect how sharp thinking feels. SCD-plus features may prompt closer evaluation but do not prove Alzheimer’s.
Why might repeat testing be useful?
A single assessment shows performance at one point in time. Repeated testing against a baseline may help clinicians identify a consistent change, including a decline that does not yet move scores outside the expected range.
Can biomarkers detect Alzheimer’s before impairment?
Chin says blood biomarkers, cerebrospinal fluid testing and amyloid PET can help investigate Alzheimer’s-related biological changes for selected patients. The commentary does not say these tests are suitable for everyone with SCD or that a biomarker result alone predicts an individual’s future.
Source: beingpatient.com
